Concern over the development of tolerance in patients on continuous intrathecal baclofen therapy has arisen as this new form of treatment for spasticity has gained wider use. We have studied time-dose relationships in 18 spinal cord injured patients who have undergone intrathecal baclofen infusion pump implantation since February 1988 in our facility. Our data show that there was a significant increase in baclofen dosage needed to control spasticity during the first 12 months post implantation. After 12 months, however, no significant change in dosage requirement was detected. In addition, there was no significant difference between completely and incompletely spinal cord injured patients with regard to both the initial dose and the tolerance trend.
Introduction
Continuous intrathecal baclofen infusion has been shown to be a safe and effective treatment for severe spasticity of spinal cord origin, and has become increasingly accepted as an alternative for surgery in spinal cord injured (SCI) patients with this problem.1-11 Nevertheless, concern over whether patients will develop tolerance re mains a controversial issue affecting clini cians' decisions whether to use this modality or not.
Tolerance is defined as a phenomenon manifested by an escalation of the dose required to produce a previously obtained effect or by the decrement of the effect produced by a given dose of drug with continued administration. 12 Baclofen (Beta-4-chlorophenyl-gamma-aminobutyric acid) is an agonist of gamma-aminobutyric acid-B (GABA-B) receptors which are very super ficial in the spinal cord. 13 A theory as to why tolerance develops for drugs which exert their pharmacological effects by interaction with specific receptors is that repeated administration of the agonist causes either a reduction in receptor number or an uncoup ling of the receptor to effector molecules. This results, either way, in an increase in the concentration of a given agent necessary to achieve the fractional occupancy in order to evoke a given effect. 14 In this study, we investigated the relation between time and the required intrathecal baclofen dose needed to keep spasticity at an acceptable level, and thereby see whether tolerance was a factor in our patients.
M a teri a ls a nd methods
Eighteen patients with SCI (5 complete, 13 incomplete) who had undergone continuous intrathecal baclofen infusion pump (Syn chroMed, Medtronics Inc) implantation in our facility between February 1988 and May 199 1 for severe spasticity were studied. All patients had temporary baclofen (Lioresal, Ciba-Geigy) infusions prior to pump im plantation, in order to find a dosage of baclofen that optimally controlled spasticity without resulting in flaccidity, and which was associated with patient satisfaction. After pump implantation, patients were seen on a monthly basis for refills and clinical investigation. We documented the initial and subsequent doses of baclofen every 3 months post implantation. We also measured the intensity of spasticity using the Ashworth scale (Table I) at the same intervals.
Results
During a mean follow up period of 29.9 months (6-48 months), spasticity was kept under acceptable control (Ashworth grade 1-2). There were no significant differences between the mean Ashworth grades at the 3-monthly intervals throughout the study. Only 10 patients have been followed for Intrathecal baclofen 517 more than 24 months. The data are still not sufficient for statistical analysis after 24 months because of the drop off rate of patients after that juncture. For that reason, we analyzed the data for the first 24 months only. All of the patients were followed for at least 6 months, 17 for 12 months, 16 for 18 months, 15 for 21 months and 14 for 24 months. All patients showed a significant trend to increase their dosage over the 24-month period (Fig 1) beginning with an initial dosage of 201.5 M-g/day (SD = 104.9). Least squares regression analysis of the dosages on 3-monthly intervals indicated that within the first 12-month period, the patients showed a significant positive linear trend at p < 0.0009 (Fig 2) . But additional analysis indicated that there was no trend in increase of dosage from the 12th month to the 24th month (Fig 3) . We also analyzed the complete and incomplete injury groups separately. Least squares regression analysis Figs 6, 7) . There was no significant increasing trend between the 12th and the 24th month for either group. We compared the complete 
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,---
----------------------, 500 - > 400L_ -___ ----; --- ::.- - - '" � 300 Ol :i 200 100 O L-----�----�------L-----� 12
Discussion
Penn and Kroin, the first authors who proposed intrathecal baclofen therapy for spinal spasticity, IS were also the first auth ors who pointed out the problem of toler ance. 1 In their series of 7 patients with spinal spasticity (due to SCI and multiple sclerosis), they reported a gradual increase in dose during the first 3-4 months in 6 patients, which extended up to 2 years in 2 patients. Ochs et al, on the other hand, reported that most of their patients reached a stable dose in 3 months except for a few patients who had experienced an increasing number of spasms even after one year, in their study with 28 patients, 10 of whom had SCI. 6 Lazorthes et al stated that they had not observed any case of pharmacological tolerance in their series of 18 patients, 7 of whom had SCI, with an average follow up of 18 months.8 Sahuquillo et al suggested that tolerance was observed only in complete SCI patients, based on their series of 9 patients (5 complete, 4 incomplete) with an average follow up of 18 months. 10 They also reported that dosage increases were statist ically significant in the first 12 months, but not between 12 and 24 months. Recently,
Meythaler et al reported the occurrence of tolerance in their 12-month follow up study in their series, including 5 SCI patients. 11 Our data with 18 SCI patients, S complete and 13 incomplete, clearly show that toler ance to baclofen administered intrathecally is observed within the first 12 months, but after the 12th month patients reach a stable dose and do not require further dosage increases. Further, there is no difference between completely and incompletely in jured patients with regard to dosage over time. None of our patients discontinued treatment due to side effects or from com plications with high doses, thus safety of this modality was not a problem in our series. We suggest that tolerance per se should not dissuade one from choosing intrathecal bac lofen pump implantation in SCI patients with severe intractable spasticity refractory to traditional modalities.
